止血剤の世界市場規模：タイプ別、製品別、用途別、エンドユーザー別、地域範囲別および予測

止血剤の市場規模と予測

止血剤市場規模は、2024年に43億米ドルと評価され、2026年から2032年にかけてCAGR 5.30%で成長し、2032年には64億9,000万米ドルに達すると予測されています。

止血剤は、手術中や緊急時に迅速かつ効果的に出血を抑えるために使用される材料です。凝固因子を濃縮したり、出血した組織に付着したり、出血部位に凝固促進因子を供給したりすることで機能します。止血剤には、機械的、能動的、受動的という特徴があります。

凝固因子がない場合の制御不能な大量出血、凝固異常、外傷による出血、脳出血、分娩後出血、大手術中または手術後の出血などの治療に使用されます。

止血剤の世界市場力学

止血剤市場を形成している主な市場力学は以下の通り：

主な市場促進要因

手術件数の増加：世界の外科手術件数の増加は、止血剤市場の主要促進要因です。世界保健機関（WHO）によると、世界中で行われる手術の件数は絶えず増加しています。Lancet誌に掲載された研究によると、2012年には世界で3億1,300万件の外科手術が行われ、2030年には4億5,840万件に増加すると予想されています。外科手術の増加は、その多くが良好な止血を必要とすることから、止血剤の需要を押し上げています。

出血性疾患の有病率の上昇：出血性疾患の有病率の増加が止血剤の需要を押し上げています。世界血友病連盟（WFH）によると、血友病は世界で約1万人に1人が罹患しています。WFHの2019年の年次世界調査では、出血性疾患患者数は世界で32万4,648人で、前年比6％増となっています。出血性疾患の患者人口の拡大により、さまざまな臨床場面で止血剤の使用が必要となっています。

外傷性傷害と緊急症例の増加：特に自動車事故による外傷の増加が止血剤市場を牽引しています。世界保健機関（WHO）の「交通安全に関する世界現状報告書2018」によると、毎年およそ135万人が交通事故によって死亡しており、さらに2,000万～5,000万人が非致死的な傷害を受けています。これらの傷害の多くは緊急止血が必要であり、救急医療や外傷治療の現場における止血剤のニーズが高まっています。

主な課題

高い止血剤コスト：止血剤は高価であり、特にヘルスケアのための資金が乏しい開発途上国では、これも大きな障壁となっています。最新の止血剤の多くは高価であるため、その費用を支払えない病院や診療所では使用できないです。この経済的障壁は、危機的状況における優れた医薬品の採用を妨げ、患者の転帰や市場全体の成長に影響を及ぼします。

副作用のリスク：ある種の止血薬には副作用の可能性があることも、市場の成長を制限しています。ヘルスケアの専門家は、アレルギー反応や組織損傷などの潜在的な副作用を懸念して、これらの製品の使用をためらっています。このような懸念から、既存の止血処置が好まれるようになり、新規止血材の市場への受け入れや使用が制限されています。

主要動向：

低侵襲手術の普及：低侵襲手術の普及が止血剤市場に大きな影響を与えています。手術手技の進歩に伴い、組織への負担や回復時間を軽減する手術が好まれるようになっています。止血剤は、周囲の組織を保護しながら出血を抑制するため、このような状況では不可欠です。この開発により、低侵襲治療に特化して設計された新規止血剤の需要が高まっています。

技術の進歩：止血剤の技術開発は市場情勢に影響を与えています。メーカー各社は、より効果的で安全な製品を開発するために研究開発費を投じています。多くの作用機序を持つコンビネーション止血剤が人気を集めています。こうした開発により、患者の予後が改善されるだけでなく、さまざまな外科領域で止血剤の用途が広がっています。

慢性疾患の蔓延：人口の高齢化と相まって慢性疾患の頻度が増加しており、止血剤の需要を押し上げています。慢性疾患は外科手術を必要とするため、出血管理が不可欠な手術の発生率が高くなります。世界人口の高齢化に伴い、外科手術の件数は増加し、止血剤市場を押し上げると予測されています。この動向は、ヘルスケア現場における適切な出血管理システムの重要性を強調しています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 止血剤市場：タイプ別

• トロンビンベースの止血剤
• ゼラチンベースの止血剤
• コラーゲン系止血剤
• 酸化再生セルロース系止血材
• コンビネーション止血剤
• フィブリンシーラント
• その他

第5章 止血剤市場：製品別

• 活性型
• パッシブ
• コンビネーション
• その他

第6章 止血剤市場：用途別

• 外傷外科
• 心臓血管外科
• 一般外科
• 形成外科
• 整形外科
• 脳神経外科

第7章 地域分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Baxter International Inc.
• Becton, Dickinson and Company（BD）
• Pfizer Inc.
• Ethicon Inc.
• B. Braun SE
• Teleflex Incorporated
• CryoLife, Inc.
• Integra LifeSciences
• Advanced Medical Solutions Group plc
• GELITA AG

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

Hemostatic Agents Market Size And Forecast

Hemostatic Agents Market size was valued at USD 4.3 Billion in 2024 and is projected to reach USD 6.49 Billion by 2032, growing at a CAGR of 5.30% from 2026 to 2032.

Hemostatic agents are materials used to control bleeding quickly and effectively during surgeries or in emergency situations. They function by concentrating coagulation factors, attaching to tissues where hemorrhage has occurred, or supplying procoagulant factors to the bleeding site. Hemostatic agents are characterized as mechanical, active, or passive.

They are used to treat uncontrollable large bleeding in the absence of clotting factors, coagulation abnormalities, hemorrhage caused by trauma, cerebral hemorrhage, postpartum hemorrhage, and bleeding during or after major surgeries.

Global Hemostatic Agents Market Dynamics

The key market dynamics that are shaping the hemostatic agents market include:

Key Market Drivers

Increasing number of Surgical Procedures: The growing number of surgical operations worldwide is a major driver of the hemostatic agents market. According to the World Health Organization (WHO), the number of procedures conducted worldwide has constantly increased. According to a study published in The Lancet, 313 million surgical procedures were performed worldwide in 2012, with the figure expected to rise to 458.4 million in 2030. The increase in surgical operations, many of which require good hemostasis, is pushing up demand for hemostatic agents.

Rising Prevalence of Bleeding Disorders: The growing prevalence of bleeding diseases is driving up the demand for hemostatic agents. According to the World Federation of Hemophilia (WFH), hemophilia affects approximately one out of every 10,000 persons worldwide. In their 2019 Annual Global Survey, the WFH found 324,648 people worldwide living with bleeding disorders, a 6% rise over the previous year. The expanding patient population with bleeding disorders necessitates the use of hemostatic agents in a variety of clinical settings.

Increasing Traumatic Injuries and Emergency Cases: The increased prevalence of traumatic injuries, notably from automobile accidents, is propelling the hemostatic agents market. According to the World Health Organization's Global Status Report on Road Safety 2018, roughly 1.35 million people die each year as a result of road traffic accidents, with another 20-50 million suffering non-fatal injuries. Many of these injuries necessitate urgent hemostasis, which increases the need for hemostatic agents in emergency and trauma care settings.

Key Challenges:

High Cost of Hemostatic Agents: Hemostatic agents are expensive, which is another major barrier, especially in developing nations where funds for healthcare are few. Many modern hemostatic products are expensive, rendering them inaccessible to hospitals and clinics that cannot pay the costs. This financial barrier impedes the adoption of good medicines in critical situations, affecting patient outcomes and overall market growth.

Risk of Adverse Reactions: The potential for adverse reactions to certain hemostatic medicines also limits market growth. Healthcare experts are hesitant to utilize these products because they are concerned about potential adverse effects such as allergic responses and tissue damage. This concern leads to a preference for existing hemostasis procedures, restricting the market's acceptance and use of new hemostatic agents.

Key Trends:

Increasing Adoption of Minimally Invasive Surgeries: The growing popularity of minimally invasive operations is having a significant impact on the hemostatic agents market. As surgical techniques advance, there is an increasing preference for operations that reduce tissue stress and recuperation time. Hemostatic medicines are essential in these situations because they help control bleeding while protecting surrounding tissues. This development is generating demand for novel hemostatic agents designed specifically for minimally invasive treatments.

Technological Advancements: Technological developments in hemostatic agents are influencing the market landscape. Manufacturers are spending in R&D to develop more effective and safe products, such as enhanced formulations and delivery technologies. Combination hemostats, which have numerous mechanisms of action, are gaining traction. These developments not only improve patient outcomes but also broaden the applications of hemostatic agents across various surgical specialties.

Growing Prevalence of Chronic Diseases: The increasing frequency of chronic diseases, combined with an aging population, is driving up demand for hemostatic agents. Chronic illnesses necessitate surgical procedures, resulting in a higher incidence of surgeries where bleeding management is essential. As the world's population ages, the number of surgical procedures is predicted to increase, boosting the market for hemostatic agents. This trend underscores the importance of appropriate bleeding management systems in healthcare settings.

Global Hemostatic Agents Market Regional Analysis

Here is a more detailed regional analysis of the hemostatic agents market:

North America:

According to Verified Market Research, North America is estimated to dominate the hemostatic agents market over the forecast period. North America has a high prevalence of cardiovascular disease, which necessitates a large number of cardiac procedures that require hemostatic agents. According to the American Heart Association's 2021 Heart Disease and Stroke Statistics update, about half of all American adults suffer from cardiovascular disease. According to the report, heart disease kills over 659,000 people in the United States each year, accounting for one out of every four deaths. Also, the Society of Thoracic Surgeons states that roughly 500,000 coronary artery bypass graft surgeries are conducted each year in the United States. This large volume of cardiac surgeries increases the demand for sophisticated hemostatic agents in the region.

Furthermore, North America has a high rate of traumatic injuries, mainly from car accidents and violence, necessitating the usage of hemostatic agents in emergency situations. According to the National Center for Health Statistics, unintentional injuries are the third greatest cause of death in the United States, with around 173,040 deaths in 2019. Also, the National Trauma Institute reports that trauma accounts for 41 million emergency department visits and 2.3 million hospital admissions across the country each year. This high volume of trauma patients greatly increases the demand for hemostatic agents in North America.

Asia Pacific:

The Asia Pacific region is estimated to exhibit the highest growth during the forecast period. The Asia-Pacific region has a high rate of traffic accidents, which result in traumatic injuries requiring hemostatic agents. According to the World Health Organization's Global Status Report on Road Safety 2018, Southeast Asia and the Western Pacific regions account for 62% of all road traffic deaths. In China alone, the Ministry of Public Security reported 203,049 road traffic accidents in 2019, with 62,763 fatalities and 226,751 injuries. The increased occurrence of traumatic injuries is increasing the demand for hemostatic agents in emergency and trauma care settings throughout Asia-Pacific.

Furthermore, the Asia-Pacific region is experiencing an increase in cardiovascular disorders, which necessitate surgical procedures and the usage of hemostatic agents. According to the Asian Pacific Society of Cardiology, cardiovascular disease (CVD) causes 35% of all fatalities in the Asia Pacific region. According to the World Heart Federation, by 2030, 4.5 million people will die from cardiovascular disease in Southeast Asia alone, up from 3.6 million in 2014. The rising prevalence of cardiovascular disorders is driving up demand for hemostatic agents in heart surgery and associated treatments.

Europe:

Europe region is estimated to exhibit substantial growth during the forecast period. Europe's significant investment in healthcare infrastructure and research is fueling innovation and acceptance of improved hemostatic agents. The European Commission states that healthcare spending in the EU reached 9.9% of GDP in 2018, with an average annual increase rate of 3.0% between 2013 and 2018. Medtech Europe reports that the European medical technology market was valued at €120 billion in 2018. This strong healthcare spending and emphasis on medical technology advancement are boosting the hemostatic agents market in Europe, as hospitals and healthcare providers invest in cutting-edge technologies to improve patient outcomes.

Furthermore, Europe has a high incidence of cardiovascular illnesses, which necessitate surgical treatments and the use of hemostatic agents. The European Heart Network claims that cardiovascular disease kills 3.9 million people in Europe each year, accounting for 45% of all deaths. According to the European Society of Cardiology, more than 11 million new instances of cardiovascular disease were diagnosed in Europe year 2015. The treatment of these disorders, particularly during surgical procedures, is driving up demand for hemostatic agents in the region.

Global Hemostatic Agents Market: Segmentation Analysis

The Hemostatic Agents Market is segmented based on Type, Product, Application, End-User, and Geography.

Hemostatic Agents Market, By Type

• Thrombin-based Hemostats
• Gelatin-based Hemostats
• Collagen-based Hemostats
• Oxidized Regenerated Cellulose-based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

Based on Type, the market is segmented into Thrombin-based, Gelatin-based, Collagen-based, Oxidized Regenerated Cellulose-based, Combination, Fibrin Sealants, and Others. The oxidized regenerated cellulose-based hemostats segment is estimated to dominate the hemostatic agents market during the forecast period. These hemostatic agents have emerged as market leaders, demonstrating their efficacy in a wide range of surgical procedures, including general surgery, cardiovascular surgery, orthopedics, and other specialties. This versatility has made them an appealing option for surgeons who face a variety of clinical settings, contributing to their dominant market position.

Hemostatic Agents Market, By Product

• Active
• Passive
• Combination
• Others

Based on Product, the market is segmented into Active, Passive, Combination, and Others. The passive segment is estimated to dominate the hemostatic agents market due to the wide range of product options and the growing popularity of technologically improved passive hemostatic solutions. These medicines are preferred for their efficacy in limiting bleeding during various surgical operations, resulting in increased acceptability among healthcare professionals. Also, the ongoing development of innovative passive hemostatic technologies by prominent manufacturers contributes to this segment's market leadership.

Hemostatic Agents Market, By Application

• Trauma
• Cardiovascular Surgery
• General Surgery
• Plastic Surgery
• Orthopedic Surgery
• Neurosurgery
• Others

Based on Application, the market is divided into Trauma, Cardiovascular Surgery, General Surgery, Plastic Surgery, Orthopedic Surgery, Neurosurgery, and Others. The general surgery segment is estimated to dominate the market over the forecast period. This dominance is driven by the growing number of surgical procedures performed worldwide, as general surgery comprises a wide range of operations that necessitate good bleeding control. The increased frequency of chronic diseases, as well as the demand for less invasive treatments, strengthen this segment, making it a vital area for hemostatic agent applications and contributing to its long-term market growth.

Hemostatic Agents Market, By End-User

• Hospitals
• Surgery Centers
• Nursing Homes
• Others

Based on End-User, the market is divided into Hospitals, Surgery Centers, Nursing Homes, and Others. The hospital segment is estimated to dominate the market over the forecast period due to the growing number of surgical procedures and the rising prevalence of chronic conditions that demand surgical interventions. Hospitals are prepared to manage difficult patients and provide comprehensive care, hence they are the principal environment for the administration of hemostatic drugs. As healthcare systems improve and expand, the need for good bleeding control in hospitals is projected to increase significantly.

Hemostatic Agents Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Hemostatic Agents Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America is estimated to dominate during the forecasted period. The region benefits from modern healthcare infrastructure, substantial healthcare spending, and a large number of surgical procedures per year. Furthermore, the existence of key market competitors and the ongoing launch of innovative hemostatic products support market growth. The growing need for technologically advanced surgical solutions reinforces North America's leadership position in this market.

Key Players

• The "Hemostatic Agents Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Baxter International, Inc., Becton, Dickinson and Company (BD), Pfizer, Inc., Ethicon, Inc., B. Braun SE, Teleflex Incorporated, CryoLife, Inc., Integra LifeSciences, Advanced Medical Solutions Group plc, and GELITA AG.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Hemostatic Agents Market Recent Developments
• In November 2023, Johnson & Johnson's MedTech division, Ethicon, launched Ethizia, a hemostatic sealing patch with European approval. This marks a substantial boost to the company's medical services in Europe.
• In August 2023, Vizient Inc. issued HemoSonics an Innovative Technology Contract for their Quantra hemostasis system.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Hemostatic Agents Market, By Type

• Thrombin-based Hemostats
• Gelatin-based Hemostats
• Collagen-based Hemostats
• Oxidized Regenerated Cellulose-based Hemostats
• Combination Hemostats
• Fibrin Sealants
• Others

5. Hemostatic Agents Market, By Product

• Active
• Passive
• Combination
• Others

6. Hemostatic Agents Market, By Application

• Trauma surgery
• Cardiovascular surgery
• General surgery
• Plastic surgery
• Orthopedic surgery
• Neurosurgery

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Baxter International Inc.
• Becton, Dickinson and Company (BD)
• Pfizer Inc.
• Ethicon Inc.
• B. Braun SE
• Teleflex Incorporated
• CryoLife, Inc.
• Integra LifeSciences
• Advanced Medical Solutions Group plc
• GELITA AG

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References